Ser68

Site Information
PPQTSGLsPsRLSKs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3211920

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	anthrax infection ( 4 )
Relevant cell line - cell type - tissue:	BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , macrophage-peritoneum [MPRIP (mouse), homozygous knockout] ( 3 ) , RAW 264.7 (macrophage) ( 2 ) , spleen ( 4 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44 25367039 Curated Info
3	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
4	Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927 21189417 Curated Info